ARA-290 vs Cartalax
A side-by-side research comparison of ARA-290 and Cartalax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ARA-290 | Cartalax |
|---|---|---|
| Full name | Cibinetide (ARA-290) | Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Investigational | Research compound (peptide bioregulator) |
| Mechanism | Selectively activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor), triggering anti-inflammatory and tissue-protective signaling while avoiding hematopoietic stimulation. | As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling. |
| Molecular weight | ~1257 Da | ~390 Da |
| Half-life | Short (minutes in plasma); effects outlast plasma levels | Short (peptide) |
| Bioavailability | High via subcutaneous injection | Oral (encapsulated) or subcutaneous |
| Typical dose | 1-4 mg per dose | ~1-2 capsules/day or short injectable courses |
| Frequency | Daily during a course | Once daily |
| Route | Subcutaneous injection | Oral capsule or subcutaneous |
ARA-290 reported benefits
- Reduces neuropathic pain
- Anti-inflammatory tissue protection
- Supports small-fiber nerve repair
- No increase in red blood cell mass (unlike EPO)
Cartalax reported benefits
- Cartilage/joint tissue support
- Connective tissue maintenance (proposed)
- Anti-inflammatory tissue signaling
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.